Since the company’s inception, Tetraphase has developed a robust antibiotics platform based on the tetracycline core chemical structure, which offers the potential to dramatically improve the treatment of serious bacterial infections. Tetraphase has utilized this fully-synthetic chemistry technology to create a pipeline of novel tetracycline antibiotics, particularly those with activity against the toughest multidrug-resistant Gram-negative bacteria.

$ 4.44 +0.17 (3.98%)
Day High: 4.49
Day Low:  4.21
Volume:    249,993
4:00 PM ET
May 27, 2016

Delayed ~20 min., by eSignal.

Press Releases

Events & Presentations

Jun 8, 2016 / 10:00 AM ET